4D Molecular Therapeutics, Inc. (FDMT) Financial Statements
4D Molecular Therapeutics, Inc. (FDMT) reported trailing twelve-month revenue of $92.0M (up 55.6% year on year) and net income of -$179.2M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$156.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
FDMT4D Molecular Therapeutics, Inc.Follow FDMT — free
—
Price chart with a free account
- Market cap
- 779.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13.4 | 18.0 | 3.1 | 20.7 | 0.0 | 85.2 | 92.0 | |
| Research & development | 53.0 | 61.4 | 80.3 | 97.1 | 141.3 | 195.7 | 240.3 | |
| Operating income | -56.7 | -71.3 | -110.0 | -112.9 | -187.8 | -159.5 | -197.1 | |
| Pre-tax income | -56.7 | -71.3 | -107.5 | -100.8 | -160.9 | -140.1 | -179.2 | |
| Income tax | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Net income | -56.7 | -71.3 | -107.5 | -100.8 | -160.9 | -140.1 | -179.2 | |
| Diluted EPS ($) | -8.82 | -2.57 | -3.32 | -2.58 | -2.98 | -2.42 | -2.55 | |
| Diluted shares (mn) | — | — | 32.4 | 39.1 | 53.9 | 57.9 | — |
USD millions · SEC XBRL
4D Molecular Therapeutics, Inc. — questions
- What is 4D Molecular Therapeutics, Inc.'s revenue?
- $92.0M over the twelve months to 2026-06-30, up 55.6% year on year, from its 10-Q and 10-K filings.
- What is 4D Molecular Therapeutics, Inc.'s net income?
- -$179.2M over the twelve months to 2026-06-30.
- What is 4D Molecular Therapeutics, Inc.'s free cash flow?
- -$156.0M over the twelve months to 2026-06-30.
- What are 4D Molecular Therapeutics, Inc.'s diluted earnings per share?
- $-2.55 over the twelve months to 2026-06-30.
Every figure on this page comes from 4D Molecular Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.